未知生产厂商
An investigational antimalarial compound (cabamiquine / DDD107498) with potent activity against multiple life-cycle stages of the Plasmodium parasite, developed at the University of Dundee; shows potential for single-dose treatment, transmission blocking and chemoprotection, and has shown efficacy with a favourable safety profile in an early-stage clinical trial.
An investigational antimalarial compound (cabamiquine / DDD107498) with potent activity against multiple life-cycle stages of the Plasmodium parasite, developed at the University of Dundee; shows potential for single-dose treatment, transmission blocking and chemoprotection, and has shown efficacy with a favourable safety profile in an early-stage clinical trial.
Inhibits Plasmodium protein synthesis by targeting translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA.
Malaria
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
